Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 22, 2020 (6 years ago)

Doxycycline Hyclate Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out-of-specification result.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Doxycycline Hyclate Tablets, USP, 100 mg, packaged in a) 3x10 unit dose cartons (NDC 0904-0430-04) and b) 5 x 10 unit dose carton (NDC 0904-0430-06), Mfd. by: West-Ward Pharmaceutical Corp., Eatontown, NJ 07724; Distributed by: Major Pharmaceuticals, 17177 N. Laurel Park Dr., Suite 233, Livonia, MI 48152.

Affected NDCs 0904-0430-04 0904-0430-06

Compare with the code on your package — it is the most precise check available.

Drug: Doxycycline Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Doxycycline Hyclate
NDC 00904-0430
100 mg/1 Tablet, Coated
Oral
Major Pharmaceuticals Rx
Recalling firm
The Harvard Drug Group
NDC code
0904-0430-04
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1288-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Doxycycline recalls

See all
Class II · Moderate risk

Doxycycline Hyclate Tablets

Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications.

Ongoing Dissolution failure Acella Pharmaceuticals, LLC NDC 42192-501-05 D-0014-2026
Class II · Moderate risk

Doxycycline

Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection

Terminated cGMP deviation Wedgewood Village Pharmacy, LLC D-1182-2022
Class II · Moderate risk

Doxycycline Capsules

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63304-616-50 D-1032-2022
Class II · Moderate risk

Doxycycline Capsules

CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

Terminated Temperature excursion Cardinal Healthcare NDC 68180-652-08 D-0178-2024

Other recalls by The Harvard Drug Group

All 2020 recalls
Class II · Moderate risk

Omega-3-Acid

Failed Capsule Specifications: Out of specification results obtained during routine stability testing for Loss on Drying of Capsule Shells.

Ongoing Failed specification The Harvard Drug Group LLC D-0493-2026